- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/605 - Glucagons
Détention brevets de la classe C07K 14/605
Brevets de cette classe: 1814
Historique des publications depuis 10 ans
|
113
|
91
|
134
|
138
|
137
|
167
|
141
|
176
|
186
|
126
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novo Nordisk A/S | 2281 |
115 |
| Eli Lilly and Company | 4089 |
91 |
| Hanmi Pharm. Co., Ltd. | 601 |
85 |
| Zealand Pharma A/S | 270 |
79 |
| Sanofi | 4293 |
46 |
| Indiana University Research and Technology Corporation | 781 |
24 |
| Sun Pharmaceutical Industries Limited | 722 |
24 |
| MedImmune Limited | 610 |
20 |
| Boehringer Ingelheim International GmbH | 4493 |
17 |
| Takeda Pharmaceutical Company Limited | 2715 |
17 |
| Hanmi Science Co., Ltd. | 135 |
16 |
| President and Fellows of Harvard College | 6091 |
15 |
| The Trustees of the University of Pennsylvania | 4414 |
15 |
| The Scripps Research Institute | 1343 |
15 |
| Ip2ipo Innovations Limited | 172 |
15 |
| I2o Therapeutics, Inc. | 32 |
15 |
| F. Hoffmann-La Roche AG | 7836 |
14 |
| Hybio Pharmaceutical Co., Ltd. | 121 |
14 |
| Amgen Inc. | 4425 |
12 |
| Duke University | 3184 |
12 |
| Autres propriétaires | 1153 |